Particularly, EMT via TGF-β/Smad pathway has been investigated in different cancer types [38,39,40,41], where TGF-β emerges as a tumor suppressor in the early stages of tumorigenesis, whereas in later stages it may favor tumor progression and metastatization via EMT activation [17,21,42,43]. This evidence concerns the gene TGFB1 and cancer.